Hefei Xingmou Biotechnology

Hefei Xingmou Biotechnology is a high-tech biotech company founded in 2019 in Anhui, China. It specializes in developing innovative gene therapies for ophthalmic diseases using advanced gene editing technologies. Its lead asset, XMVA09—a novel AAV-based dual-antibody gene therapy targeting Angiopoietin 2 and VEGF—has received IND approval from the Chinese NMPA for wet age-related macular degeneration. Early clinical studies have shown significant benefit with no drug-related adverse events, attributed to its low immunogenicity and new intravitreal delivery shell design. The company’s pipeline also includes programs targeting diabetic macular oedema, arthritis, congenital disorders, endocrinology/metabolic disease, nervous system disease, and immune system disease.